NY-CLARITY-AI
19.9.2022 14:02:20 CEST | Business Wire | Press release
Clarity AI, the leading global sustainability tech platform, announced today that it believes the positive viral attention Patagonia received last week and the negative viral attention H&M and other fast-fashion brands received over the past few months is clouding the picture of what can actually save the planet.
A few days ago, Yvon Chouinard – the Chairman of Patagonia – announced that he will be donating the entire company, worth $3 billion, to fight climate change. Social networks were on fire sharing the news and supporting Chouinard – CEOs, fashion models, and millions of consumers. The story went viral. Another viral story from earlier this summer is related to fast-fashion giant H&M. It is facing a class-action lawsuit, brought by a student at SUNY New Paltz, for using misleading sustainability claims and for employing the fast-fashion business model while working to be more sustainable.
Around the same time, regulators in Europe bore down on the use of inaccurate data or misleading claims. The Norwegian Consumer Authority (NCA) concluded that H&M’s usage of sustainability data was non-compliant. Then, the UK’s Competitions and Markets Authority opened an investigation to scrutinize the sustainability claims made by 3 brands – ASOS, Boohoo, and Walmart-owned George at Asda. The Netherlands’ Authority for Consumer Markets (ACM) followed and put H&M and Decathlon, the largest sporting goods retailer in the world, under investigation for using misleading “green” claims. And considering 60% of the top 20 fashion conglomerates by market cap have similar sustainability claims, Clarity AI believes this is just the beginning of whitewashing the green out of fashion.
“A very large fast-fashion company can have a globally-sized impact on sustainability. And, in terms of size, H&M is 1.5% of the fashion industry and is more than 15 times bigger than Patagonia,” notes Rebeca Minguela, Founder & CEO, of Clarity AI. “Yes, the fast-fashion model, which is approximately 10% of the fashion industry, generates waste and fuels consumerism, but it is not acceptable to say the entire industry cannot push to be more sustainable or that it is solely to blame for the planet’s woes.”
How does H&M’s size relate to carbon emissions and potential emissions reduction? When looking at the intensity of carbon emissions (CO2 per dollar of revenue), Patagonia performs more than twice as well as H&M. H&M has committed to get to that intensity level by 2030, and it is on track so far. Should it achieve its goal, H&M will be at almost exactly the same level of carbon emissions intensity that Patagonia is today. That would mean that H&M would successfully reduce 56% of their emissions, which is the same as 8 million flights from London to NYC or 21 times Patagonia’s yearly emissions.
“The reality is that advanced technology models actually allow us to improve the data displayed on those labels,” added Ms. Minguela. “We can measure more, and better. We should encourage H&M and the rest of the fashion industry – the other 98.5% – to add those improved sustainability labels and for consumers to use that information.”
About Clarity AI
Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, organizations, and consumers. As of August 2022, Clarity AI’s platform analyzes more than 50,000 companies, 300,000 funds, 198 countries and 188 local governments – 2-13 times more than any other player in the market – and delivers data and analytics for investing, corporate research, benchmarking, consumer ecommerce and reporting. Clarity AI has offices in North America, Europe and the Middle East, and its investor client network manages tens of trillions in assets under management. clarity.ai
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005361/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
